The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design.

The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design.

BACKGROUND: HIV reverse transcriptase (RT) is a key target of anti-AIDS therapies. Structural studies of HIV-1 RT, unliganded and complexed with different non-nucleoside inhibitors (NNIs), have pointed to a common mode of binding and inactivation through distortion of the polymerase catalytic site b...

Descripció completa

Dades bibliogràfiques
Autors principals:	Ren, J, Esnouf, R, Hopkins, A, Ross, C, Jones, Y, Stammers, D, Stuart, D
Format:	Journal article
Idioma:	English
Publicat:	1995

Ítems similars

Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors.
per: Esnouf, R, et al.
Publicat: (1995)

Crystallographic analysis of the binding modes of thiazoloisoindolinone non-nucleoside inhibitors to HIV-1 reverse transcriptase and comparison with modeling studies.
per: Ren, J, et al.
Publicat: (1999)

Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor.
per: Esnouf, R, et al.
Publicat: (1997)

Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives.
per: Ren, J, et al.
Publicat: (1998)

Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors.
per: Hopkins, A, et al.
Publicat: (1996)

Continuous and discontinuous changes in the unit cell of HIV-1 reverse transcriptase crystals on dehydration.
per: Esnouf, R, et al.
Publicat: (1998)

Phenylethylthiazolylthiourea (PETT) non-nucleoside inhibitors of HIV-1 and HIV-2 reverse transcriptases. Structural and biochemical analyses.
per: Ren, J, et al.
Publicat: (2000)

Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.
per: Hopkins, A, et al.
Publicat: (2004)

3'-Azido-3'-deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range conformational changes.
per: Ren, J, et al.
Publicat: (1998)

Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase.
per: Ren, J, et al.
Publicat: (2008)

HIV reverse transcriptase structures: designing new inhibitors and understanding mechanisms of drug resistance.
per: Ren, J, et al.
Publicat: (2005)

Cloning, expression, purification, and crystallisation of HIV-2 reverse transcriptase.
per: Bird, L, et al.
Publicat: (2003)

Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors.
per: Ren, J, et al.
Publicat: (2002)

Crystals of HIV-1 reverse transcriptase diffracting to 2.2 A resolution.
per: Stammers, D, et al.
Publicat: (1994)

Allosteric inhibitors against HIV-1 reverse transcriptase: design and synthesis of MKC-442 analogues having an omega-functionalized acyclic structure.
per: Tanaka, H, et al.
Publicat: (1998)

2-Amino-6-arylsulfonylbenzonitriles as non-nucleoside reverse transcriptase inhibitors of HIV-1.
per: Chan, J, et al.
Publicat: (2001)

Binding of the second generation non-nucleoside inhibitor S-1153 to HIV-1 reverse transcriptase involves extensive main chain hydrogen bonding.
per: Ren, J, et al.
Publicat: (2000)

THE GROWTH AND CHARACTERIZATION OF CRYSTALS OF HUMAN-IMMUNODEFICIENCY-VIRUS (HIV) REVERSE-TRANSCRIPTASE
per: Jones, E, et al.
Publicat: (1993)

Structural characterization of HIV reverse transcriptase: a target for the design of specific virus inhibitors.
per: Tisdale, M, et al.
Publicat: (1989)

Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
per: Freeman, G, et al.
Publicat: (2004)

Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase.
per: Ren, J, et al.
Publicat: (2000)

Models which explain the inhibition of reverse transcriptase by HIV-1-specific (thio)carboxanilide derivatives.
per: Esnouf, R, et al.
Publicat: (1997)

Biaryl acids: novel non-nucleoside inhibitors of HIV reverse transcriptase types 1 and 2.
per: Milton, J, et al.
Publicat: (1998)

Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors.
per: Ren, J, et al.
Publicat: (2001)

Crystal structures of HIV-1 reverse transcriptases mutated at codons 100, 106 and 108 and mechanisms of resistance to non-nucleoside inhibitors.
per: Ren, J, et al.
Publicat: (2004)

HEPT: From an investigation of lithiation of nucleosides towards a rational design of non-nucleoside reverse transcriptase inhibitors of HIV-1
per: Tanaka, H, et al.
Publicat: (1999)

Novel 2-Chloro-8-arylthiomethyldipyridodiazepinone Derivatives with Activity against HIV-1 Reverse Transcriptase
per: Supanna Techasakul, et al.
Publicat: (2007-02-01)

Mutational analysis of Tyr-318 within the non-nucleoside reverse transcriptase inhibitor binding pocket of human immunodeficiency virus type I reverse transcriptase.
per: Pelemans, H, et al.
Publicat: (1998)

Approved HIV reverse transcriptase inhibitors in the past decade
per: Guangdi Li, et al.
Publicat: (2022-04-01)

Tanrı İnanç Biçimleri Ölçeğinin (TİBO) Geliştirilmesi (Geçerlik ve Güvenirlik Çalışması)
per: Abdulvahap Taştan, et al.
Publicat: (2023-06-01)

STRUCTURAL STUDIES ON HUMAN-IMMUNODEFICIENCY-VIRUS REVERSE-TRANSCRIPTASE
per: Stammers, D, et al.
Publicat: (1990)

A mutation in the 3' region of the human immunodeficiency virus type 1 reverse transcriptase (Y318F) associated with nonnucleoside reverse transcriptase inhibitor resistance.
per: Harrigan, P, et al.
Publicat: (2002)

Inhibition of HIV-1 reverse transcriptase by defined template/primer DNA oligonucleotides: effect of template length and binding characteristics.
per: Idriss, H, et al.
Publicat: (1994)

HIV-1 reverse transcriptase: crystallization and analysis of domain structure by limited proteolysis.
per: Lowe, D, et al.
Publicat: (1988)

Lipidic strategy for improving bioavailability of nucleoside HIV reverse transcriptase inhibitor
per: N. S. Shastina, et al.
Publicat: (2011-04-01)

A novel mutation (F227L) arises in the reverse transcriptase of human immunodeficiency virus type 1 on dose-escalating treatment of HIV type 1-infected cell cultures with the nonnucleoside reverse transcriptase inhibitor thiocarboxanilide UC-781.
per: Balzarini, J, et al.
Publicat: (1998)

Formation of heterodimers of human-immunodeficiency-virus-type-1 reverse transcriptase by recombination of separately purified subunits.
per: Stammers, D, et al.
Publicat: (1992)

Structural basis for the improved drug resistance profile of new generation benzophenone non-nucleoside HIV-1 reverse transcriptase inhibitors.
per: Ren, J, et al.
Publicat: (2008)

Inhibitors of HIV-1 Reverse Transcriptase—Associated Ribonuclease H Activity
per: Michael A. Parniak, et al.
Publicat: (2012-10-01)

Focus on Chirality of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors
per: Valeria Famiglini, et al.
Publicat: (2016-02-01)